Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience
Journal of Neuro-Oncology, 08/14/09
Lwu S et al. - In a study to examine peri-operative anti-epileptic drugs (AED) practice patterns in newly-diagnosed pts with malignant glioma to determine if there is deviation from published guidelines, it was found that pts receiving peri-operative AED prophylaxis were common, had a trend to reduced peri-operative seizures, and had few adverse effects. Most pts were maintained on prophylactic AED continued beyond the first peri-operative week, contradicting published guidelines. Increased awareness of practice guidelines may help modify AED prescription patterns in malignant glioma pts.
Methods- A retrospective chart review was performed in adult pts with newly diagnosed malignant gliomas undergoing surgery.
- Demographic information, AED use, seizure incidence, adverse effects, tumor size, and tumor location were recorded.
- Of 164 eligible pts, 54 (33%) presented with seizures and all received AED.
- Prophylactic AED were given to 44 pts (27%).
- Peri-operative seizures (within 1 wk) occurred in 2 pts without (3%) and no pts with seizure prophylaxis.
- Adverse AED reactions and adverse effects attributable to seizures were both rare.
- Prophylactic AED were continued >1 wk post-op in 30 pts (18%).
- Pts receiving prophylactic AED were more likely to have had tumors involving the temporal lobe than those who did not (50 vs 20%.
Related Articles
Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides
Expert Review of Anticancer Therapy, 11/12/09
Relevance Score: 79%
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
BMC Cancer, 10/22/09
Relevance Score: 79%
MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells
Journal of Neuro-Oncology, 11/04/09
Relevance Score: 68%
Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma
The Journal of Nuclear Medicine, 11/18/09
Relevance Score: 67%
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Neuro-Oncology, 10/06/09
Relevance Score: 67%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Glioblastoma Proto-oncogene SEC61gamma Is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress
Cancer Research, 12/10/09
Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology
Cancer Research, 12/10/09
Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974–2003
Journal of the National Cancer Institute, 12/10/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Anti Insulin-Like Growth Factor I Receptor Immunoliposomes: A Single Formulation Combining Two Anticancer Treatments with Enhanced Therapeutic Efficiency
Journal of Clinical Endocrinology and Metabolism, 12/11/09
HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies
Expert Opinion in Pharmacotherapy, 12/11/09
Zoledronic acid: an unending tale for an antiresorptive agent
Expert Opinion in Pharmacotherapy, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


